Next Phase Newsletter

A global investment firm focuses on private venture and growth assets. The firm manages over USD 2 billion and invests in highly innovative and disruptive companies in the biotechnology, enterprise-facing core technology, and consumer sectors. The firm is open to global companies in Pre-Seed to Series B rounds and prefers to lead its investments. The firm is capable of investing up to $25M USD. 
 
Within life sciences, the firm invests in therapeutics and med-techs with strong preference in aging-related indications including, but not limited to, oncology, immunology, neurology, ophthalmology, cardiovascular, liver, and kidney diseases. The firm typically avoids rare diseases as the firm emphasizes breakthrough technologies. The firm is open to company being as early as discovery stages. 
 
The firm prefers to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the US actively invests and provides support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 60 companies and continues to actively seek life science investments with its third fund, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China. 
 
The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment. 
 
The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A boutique venture capital firm with offices in US and the Middle East has invested alongside Tier 1 VCs in several companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies. 
 
The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity.  

 
The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A private investment firm launched a healthtech-dedicated fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities. 
 
The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine). 
 
The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare and life sciences focused venture capital firm with US and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.

The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.

The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Silicon Valley-based VC fund is focused on early-stage ( Seed, Series A/B ) AI companies in Healthcare, Enterprise, and Automation. With a mission-driven thesis of doing well by doing good, the firm invest in technical founders keen on applying AI to solve some of the acutest problems faced across industries. The firm is currently investing from its second fund which is focusing on applied AI for Healthcare ( Precision Medicine, AI Drug Development, Gene/Cell Therapies Delivery, Oncology, Medical Imaging, Digital Healthcare), Enterprise ( Co-Pilots for Enterprise, Cybersecurity, DevOps/MLOps Tools, Infrastructure), and Automation ( Robotics, Autonomous Driving, Drones ). 

The firm’s team is a multidisciplinary team of seasoned founders, deep technologists/scientists, and healthcare practitioners united by a drive to nurture the next wave of startups transforming lives through AI. 

The firm can invest from Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. 
 
In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets. 
 
The firm prefers to take a board seat however, it is not required. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US is particularly interested in tech companies generating data. The firm takes a close look at amount and quality of generated data. The firm is focused on early stages, specifically Seed and Series A. The firm’s typical check size is between $1M-$5M in equity, typically investing in 20 companies each year. The firm is focused on USA based companies. 
 
The firm is focused on digital health and techbio (typically looked at as the intersection of life sciences and AI). Previous investments include single-cell protein sequencing, a company using AI for tech-enabled drug discovery, and a company developing mRNA Therapeutics for Cancers. The firm has no revenue requirements for companies. 
 
The firm can both lead and co-invest and will consider a board seat on a case-by-case basis. The firm has no requirements for the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.